CYLD mediated deubiquitination of DDX58 (RIG-I)

Stable Identifier
R-HSA-936390
Type
Reaction [omitted]
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
CYLD is an ovarian tumor (OTU) domain-containing deubiquitinating enzyme (DUB) and has been identified as a negative regulator of DDX58 (RIG-I) mediated antiviral signaling. CYLD associates with the CARD domain of DDX58 and removes K63-linked ubiquitin from the DDX58 CARDs that are conjugated by the E3 ubiquitin ligase, TRIM25 and RNF135.
Literature References
PubMed ID Title Journal Year
18636086 The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response

Horvath, CM, Moran, TM, Yount, JS, Ng, A, Legarda-Addison, D, Xavier, R, Komuro, A, Ting, AT, O'Donnell, MA, Basler, CF, Cardenas, WB, Friedman, CS

EMBO Rep 2008
18467330 Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD

Wright, A, Lee, AJ, Zhang, M, Sun, SC, Jin, W, Imaizumi, T, Chang, M, Wu, X

J Biol Chem 2008
Participants
Participates
Catalyst Activity

Lys63-specific deubiquitinase activity of CYLD [cytosol]

Orthologous Events
Authored
Reviewed
Created
Cite Us!